BA
SRPT icon

Bridgewater Associates’s Sarepta Therapeutics SRPT Stock Holding History

Bridgewater Associates’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.73M Buy
152,068
+17,791
+13% +$336K 0.01% 624
2026
Q1 		$2.92M Sell
134,277
-146,291
-52% -$2.83M 0.01% 567
2025
Q4 		$6.04M Sell
280,568
-71,707
-20% -$1.51M 0.02% 477
2025
Q3 		$6.79M Buy
+352,275
New +$6.28M 0.03% 419
2025
Q2 		– Sell
-19,820
Closed -$1.26M – 716
2025
Q1 		$1.26M Buy
19,820
+14,575
+278% +$1.53M 0.01% 500
2024
Q4 		$638K Buy
+5,245
New +$643K ﹤0.01% 555
2024
Q2 		– Sell
-23,222
Closed -$3.01M – 933
2024
Q1 		$3.01M Sell
23,222
-3,166
-12% -$388K 0.02% 440
2023
Q4 		$2.54M Sell
26,388
-24,076
-48% -$2.31M 0.01% 480
2023
Q3 		$6.12M Buy
50,464
+19,608
+64% +$2.22M 0.04% 316
2023
Q2 		$3.53M Buy
30,856
+386
+1% +$49.8K 0.02% 371
2023
Q1 		$4.2M Sell
30,470
-27,465
-47% -$3.56M 0.03% 344
2022
Q4 		$7.51M Sell
57,935
-40,473
-41% -$4.69M 0.04% 287
2022
Q3 		$10.9M Sell
98,408
-27,110
-22% -$2.73M 0.06% 243
2022
Q2 		$9.41M Buy
125,518
+121,144
+2,770% +$8.91M 0.04% 344
2022
Q1 		$342K Buy
+4,374
New +$335K ﹤0.01% 927
2021
Q3 		– Sell
-3,838
Closed -$298K – 788
2021
Q2 		$298K Sell
3,838
-370
-9% -$28.1K ﹤0.01% 685
2021
Q1 		$314K Buy
+4,208
New +$388K ﹤0.01% 414

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Bridgewater Associates's SRPT Position: Q2 2026 in Review

Bridgewater Associates increased its Sarepta Therapeutics (SRPT) stake by 13% in Q2 2026, buying an estimated $336K and bringing the position to 152,068 shares worth $2.73M. The position accounts for 0.01% of the portfolio, ranked #624.

Bridgewater Associates first reported a position in SRPT in Q1 2021 and has held it in 17 quarters since. The position peaked at $10.9M in Q3 2022. 324 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Bridgewater Associates held 152,068 shares of Sarepta Therapeutics worth $2.73M as of Q2 2026.
  • Bridgewater Associates bought 17,791 Sarepta Therapeutics shares in Q2 2026, an estimated $336K.
  • Sarepta Therapeutics made up 0.01% of Bridgewater Associates's portfolio in Q2 2026, its #624 holding.
  • Bridgewater Associates first reported a position in Sarepta Therapeutics in Q1 2021 and has held it in 17 quarters since.
  • Bridgewater Associates's Sarepta Therapeutics position peaked at $10.9M in Q3 2022.
  • 324 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Bridgewater Associates's 13F filing for Q2 2026, filed 14 Aug 2026.